Discover a world of educational opportunities to support your lifelong learning
Practice Experience Program is a self-directed education program designed to support non vocationally registered doctors on their pathway to RACGP Fellowship
RACGP offer courses and events to further develop the knowledge you need to develop your GP career
2022 RACGP curriculum and syllabus
for Australian general practice
The Abuse and violence: working with our patients in general practice provides the best-available current evidence for GPs
Stay up-to-date with the latest information and resources on the COVID-19 vaccine rollout.
Download the Standards for general practice (5th edition) - a benchmark for quality care and risk management in Australian general practices
Coronavirus (COVID-19) resources for general practitioners
Advice and guidelines for GPs and practice teams to help protect general practice information systems
Video consultations can provide convenient and accessible healthcare delivery
Read all of the RACGP reports and submissions on various healthcare topics
Read all of the RACGP position statements on various healthcare topics
Join our RACGP Facebook groups
Oral treatments for COVID-19 – Prescribing information for GPs
Adults who have mild to moderate COVID-19 confirmed by a PCR or medically verified RAT and who can start treatment within five days of symptom onset, can be prescribed PBS-subsidised Lagevrio if:
When prescribing Lagevrio via the PBS, ensure the patient meets the eligibility criteria outlined on the PBS listing.
National Clinical Evidence Taskforce recommendations
The latest recommendation on the use of Lagevrio from the National Clinical Evidence Taskforce is ‘Do not routinely use molnupiravir for the treatment of COVID-19.’
The Taskforce has stated that there may be specific circumstances for the highest risk patients, where all other treatment options are contraindicated or inappropriate, in which non-routine use of Lagevrio might be considered. See the Taskforce’s rationale for the updated recommendations.
Please note that the PBS eligibility for Lagevrio is broader than the Taskforce recommendations.
The standard dose of Lagevrio is 800 mg (administered as four 200 mg capsules), taken every 12 hours for five days, with or without food.
Lagevrio should be taken regularly at the same time each day. If a dose is missed and it has been less than 10 hours since the last dose the patient can take it as soon as it is remembered. If it has been more than 10 hours since the missed dose this should be skipped, and the next dose taken at the scheduled time. A double dose should not be taken to make up for a missed dose. Patients should not stop taking Lagevrio without speaking to their GP or physician.
The capsules should not be opened, broken or crushed, and must be swallowed whole.
A person should not take Lagevrio if they are allergic to molnupiravir or any of the other ingredients listed in the product information, listed below.
To date, there have been no medicine interactions identified with Lagevrio based on the limited data currently available.
Lagevrio is not recommended during pregnancy.
People of childbearing potential should use effective contraception for the duration of treatment and for four days after the last dose of Lagevrio. Men who are sexually active with a person of childbearing potential should use an effective contraception during treatment and for three months after treatment with Lagevrio.
Breastfeeding is not recommended during treatment and for four days after the last dose of Lagevrio.
The most common side effects of Lagevrio are diarrhoea, nausea and dizziness. These side effects can lead to significant morbidity in frail and elderly patients, including dehydration, delirium and increased falls risk. It is important older people who are administered Lagevrio are closely monitored. Patients should be advised to speak with their GP or prescribing physician if they are concerned about any side effects while taking the medication.
Did you know you can now log your CPD with a click of a button?